AGEN - Agenus Loses More Than 50% Value On Thursday - Here's Why | Benzinga
Agenus Inc. (NASDAQ:AGEN) stock is trading lower on Thursday, with a session volume of 6.29 million, according to data from Benzinga Pro.
The company announced the results of its end-of-Phase 2 (EOP2) meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
The FDA discouraged the accelerated approval pathway and advised against submitting these results to support an Accelerated Approval based on its view that objective response rates may not translate to survival benefits.
Agenus previously disclosed data from the Phase 1 trial, which ...